Kaberniuk A A, Oliĭnyk O S, Kolybo D V, Komisarenko S V
Ukr Biokhim Zh (1999). 2009 May-Jun;81(3):92-101.
Development of complications during diphtheria depends to a large extent on toxin-neutralizing antibodies level in the patient's blood. Active immunization of people with diphtheria anatoxin is widely used for diphtheria prevention and passive immunization with hyperimmune antitoxic horse serum is used for diphtheria treatment. A traditional component of anti-diphtheria vaccines--diphtheria anatoxin has a number of serious disadvantages, which are mainly associated with complicated procedure of its production. Thus, the search for new antigen substances, which can effectively stimulate protective humoral response to diphtheria toxin, is an urgent task in anti-diphtheria vaccine development. Furthermore, one of the most important objects is the development of new in vitro methods for estimation of diphtheria toxin-neutralizing polyclonal and monoclonal antibodies, which allow to avoid using active diphtheria toxin and toxin-sensitive laboratory animals. Comparative studies of toxin-neutralizing antibodies induction after immunization of laboratory animals with recombinant subunits A and B of diphtheria toxin were carried out. The new method for detection of protective antibodies in serum was proposed. This method is based on the ToBI test (Toxin Binding Inhibition test); namely on the property of anti-diphtheria antibodies to inhibit the biding of toxin subunit B fused with enhanced green fluorescent protein (EGFP) to the sensitive to diphtheria toxin Vero cells. The ability of subunit B to induce toxin-neutralizing antibodies in laboratory animals (rabbits and guinea pigs) was confirmed by the intradermal test, which is traditionally used to detect protective antitoxic antibodies in the serum, and by flow cytometry method, developed for this purpose. The results suggest that diphtheria toxin recombinant subunit B may be used for the induction of the protective immune response. The new developed approach for estimation diphtheria toxin-neutralizing antibodies is more ethical and safe and can substitute successfully the traditional methods.
白喉并发症的发生在很大程度上取决于患者血液中毒素中和抗体的水平。用白喉类毒素对人群进行主动免疫广泛用于预防白喉,而用超免疫抗毒素马血清进行被动免疫则用于治疗白喉。抗白喉疫苗的传统成分——白喉类毒素有许多严重缺点,主要与其复杂的生产过程有关。因此,寻找能有效刺激对白喉毒素产生保护性体液反应的新抗原物质是抗白喉疫苗研发中的一项紧迫任务。此外,最重要的目标之一是开发新的体外方法来评估白喉毒素中和多克隆和单克隆抗体,这可以避免使用活性白喉毒素和对毒素敏感的实验动物。对用白喉毒素重组亚基A和B免疫实验动物后诱导毒素中和抗体的情况进行了比较研究。提出了血清中保护性抗体的新检测方法。该方法基于ToBI试验(毒素结合抑制试验);即基于抗白喉抗体抑制与增强型绿色荧光蛋白(EGFP)融合的毒素亚基B与对白喉毒素敏感的Vero细胞结合的特性。通过传统用于检测血清中保护性抗毒素抗体的皮内试验以及为此目的开发的流式细胞术方法,证实了亚基B在实验动物(兔子和豚鼠)中诱导毒素中和抗体的能力。结果表明,白喉毒素重组亚基B可用于诱导保护性免疫反应。新开发的评估白喉毒素中和抗体的方法更符合伦理且更安全,能够成功替代传统方法。